PharmaCieloPCLOF -4.35% FCF Margin % is 87.70% as of Dec. 2025. The stock has 5 warning signs investors should review. Among 958 Drug Manufacturers companies, PharmaCielo ranks worse than 89.04% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. PharmaCielo's Free Cash Flow for the
three
months ended in Dec. 2025 was $0.39 Mil. PharmaCielo's Revenue for the
three
months ended in Dec. 2025 was $0.44 Mil. Therefore, PharmaCielo's FCF Margin % for the quarter that ended in Dec. 2025 was 87.70%.
The historical rank and industry rank for PharmaCielo's FCF Margin % or its related term are showing as below:
PCLOF'
s FCF Margin % Range Over the Past 10 Years
Min: -4569.25 Med: -1054.94 Max: -46.89
Current: -46.89
During the past 7 years, the highest FCF Margin % of PharmaCielo was -46.89%. The lowest was -4569.25%. And the median was -1054.94%.
PCLOF's FCF Margin % is ranked worse than 89.04% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs PCLOF: -46.89
PharmaCielo FCF Margin % Related Terms
PharmaCielo FCF Margin % Historical Data
* Premium members only.
The historical data trend for PharmaCielo's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaCielo's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCielo FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaCielo's FCF Margin % distribution charts can be found below:
* The bar in red indicates where PharmaCielo's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCielo (PCLOF) has a FCF Margin % of 87.70% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on PharmaCielo and its competitors. According to the industry distribution chart, PharmaCielo ranks #853 out of 958 companies in the Drug Manufacturers industry, placing it in the top 89%.
Is PharmaCielo's FCF Margin % too high?
PharmaCielo's current FCF Margin % is 87.70%. The Drug Manufacturers industry median FCF Margin % is 2.51. PharmaCielo's value of 87.70% is 3394% above this industry median. Based on the distribution chart, PharmaCielo ranks #853 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does PharmaCielo's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, PharmaCielo ranks #853 out of 958 companies for FCF Margin %. This places PharmaCielo in the lower half of its industry. The industry median FCF Margin % is 2.51. PharmaCielo's value of 87.70% is 3394% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCielo's current FCF Margin % of 87.70% is 3394% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on PharmaCielo and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCielo's current FCF Margin % is 87.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.10, compared to a current price of $0.05 — trading 48.5% below its estimated fair value. The current FCF Margin % is 87.70% and 3394% above the Drug Manufacturers industry median of 2.51. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current FCF Margin % is 87.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCLOF has been successfully added to your 